The literature demonstrated that SGLT2i may be cost-effective compared to many antidiabetic therapies including DPP-4i, SU, TZD, AGI, insulin, and standard care (Economics and Policy in Diabetes)
Diabetes News
Glycosmedia is dedicated to bringing free, non-promotional, editorially independent news to a global audience about developments in diabetes, and is primarily aimed at health professionals.
New ABCD Resource: SGLT-2 inhibitors in people with type 2 diabetes
We hope that this document will help pragmatically support those involved in the day to day care of people with type 2 diabetes in the “here and now”, with the aim of maximizing the benefits and minimizing harm
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure
Based on these findings, liraglutide should be considered suitable for patients with T2D with or without a history of NYHA functional class I to III HF (Journal of the American College of Cardiology)
FDA Proposes Broad Approach for Conducting Safety Trials for Type 2 Diabetes Medications
New Draft Guidance Considers Broader Evaluations Beyond Cardiovascular Outcomes Trials
Efficacy of SGLT-2 inhibitors in older adults with diabetes: systematic review with meta-analysis of cardiovascular outcome trials
The results are reassuring, as they confirm that the efficacy profile of gliflozins is unchanged by age, and may further enhance the CV protection offered by statin (Diabetes Research and Clinical Practice)
Initial Glycemic Control and Care Among Younger Adults Diagnosed With Type 2 Diabetes
Adults with onset of type 2 diabetes at a younger age were less likely to achieve glycemic control at 1 year following diagnosis, suggesting the need for tailored care approaches to improve outcomes for this high-risk patient population (Diabetes Care)
Haptoglobin Phenotype Modifies the Influence of Intensive Glycemic Control on Cardiovascular Outcomes
Intensive glucose-lowering therapy was effective at preventing incident coronary heart disease and CVD events in ACCORD study participants with the Hp2-2 phenotype but not in Hp1 carriers, who had increased mortality risk from intensive therapy (Journal of the American College of Cardiology)
Iron metabolism and type 2 diabetes mellitus: A meta‐analysis and systematic review
The elevated serum ferritin was one of the risk factors for type 2 diabetes, and soluble transferrin receptor‐to‐ferritin ratio was inversely related to the risk of type 2 diabetes. A systematic review showed that serum transferrin and hepcidin might be directly or indirectly related to the development of diabetes (Journal of Diabetes Investigation)
Retinopathy develops at similar glucose levels but higher HbA1c levels in people with black African ancestry compared to white European ancestry: evidence for the need to individualize HbA1c interpretation
Since retinopathy occurs at higher HbA1c levels in black people for a given level of average plasma glucose, strategies may be needed to individualize the interpretation of HbA1c measurements (Diabetic Medicine)
Sodium–glucose co‐transporter‐2 inhibitor cardiovascular outcome trials and generalizability to English primary care
There was variation in proportions of the primary care type 2 diabetes population fulfilling inclusion criteria of SGLT‐2i CVOTs. The more stringent the inclusion criteria, the lower the proportion identified in a primary care setting. Prescription rates for SGLT‐2is were low in this national database, and there were demographic disparities in prescribing (Diabetic Medicine)
Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update
This review describes the present evidence on diverse pharmacological and therapeutic aspects for various SGLT2 inhibitors, as an attempt to provide useful guidance for optimum application in clinical practice (Diabetes Therapy)
Can the Cardiovascular Risk Reductions Observed with Empagliflozin in the EMPA‐REG OUTCOME Trial be Explained by Concomitant Changes Seen in Conventional Cardiovascular Risk Factor Levels?
Empagliflozin‐associated changes in conventional CV risk factors in EMPA‐REG OUTCOME appear to explain only a small proportion of the CV and all‐cause death reductions observed. Alternative risk‐reduction mechanisms need to be explored to determine if the observed CV risk changes can be explained by other factors, or possibly by a direct drug‐specific effect (Diabetes, Obesity and Metabolism)
Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression
In people with type 2 diabetes and normoalbuminuria, a high-risk score from the urinary proteomic classifier CKD273 was associated with an increased risk of progression to microalbuminuria over a median of 2·5 years, independent of clinical characteristics. However, spironolactone did not prevent progression to microalbuminuria in high-risk patients (The Lancet Diabetes & Endocrinology)
A metabolomics based molecular pathway analysis for how the SGLT2‐inhibitor dapagliflozin may slow kidney function decline in patients with diabetes
The observed molecular pathways targeted by dapagliflozin and associated with DKD suggest that modifying molecular processes related to energy metabolism, mitochondrial function, and endothelial function may contribute to its renal protective effect (Diabetes, Obesity and Metabolism)
Value of Capillary Glucose Profiles in Assessing Risk of Nocturnal Hypoglycemia in Type 1 Diabetes Based on Continuous Glucose Monitoring
Nocturnal hypoglycemia constitutes nearly one-third of hypoglycemic events in people with T1D. Strict glycemic control and great fluctuation of glucose are potential contributory factors. Daily SMBG profiles and the BGn model could help assess the risk of nocturnal hypoglycemia in T1D, which may support further development of preventive strategies (Diabetes Therapy)
National Diabetes Statistics Report
Estimates of Diabetes and Its Burden in the United States (CDC)
Time spent outside of target glucose range for young children with type 1 diabetes: a continuous glucose monitor study
On average, participants spent the majority (13 h) of the day in hyperglycaemia (>10.0 mmol/l) and a median of ~1 h/day in hypoglycaemia (<3.9 mmol/l). Participants with minority race/ethnicity and higher parent education levels spent more time in target range, 3.9–10.0 mmol/l, and less time in hyperglycaemia (Diabetic Medicine)
Record high two million people at risk of Type 2 Diabetes
Around two million people in England are at risk of developing Type 2 diabetes, the highest on record, according to new NHS figures
Self-Monitoring of Blood Glucose Requirements with the Use of Intermittently Scanned Continuous Glucose Monitoring
These findings have important implications for cost-effectiveness and for decision-making around insulin dose calculations and driving. Our findings emphasize the need for continued SMBG testing among people at high risk of hypoglycemia who use isCGM. Cost-effectiveness analyses for isCGM may require revision (Diabetes Technology and Therapeutics)
SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action
There is compelling evidence that sodium–glucose cotransporter 2 (SGLT2) inhibitors exert cardioprotective and renoprotective effects that are far greater than expected based on their effects on glycemia or glycosuria (Diabetes Care)
Glycosmedia is also available as an App: